cgoncology_cover.jpg
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
June 18, 2024 08:00 ET | CG Oncology Inc.
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
Picture1.png
Bionano Laboratories Announces New Category I CPT Code for OGM Use in Hematological Malignancy Analysis
June 17, 2024 16:05 ET | Bionano Laboratories
American Medical Association issues Category I CPT code for the use of optical genome mapping in genome-wide analysis related to hematological malignancies
finacialnews-logo-final-01 (2).png
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
June 17, 2024 09:45 ET | FN Media Group LLC
PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - According to a report from Mordor Intelligence the Acute Myeloid Leukemia Market size is estimated at USD 1.83...
finacialnews-logo-final-01 (2).png
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
June 17, 2024 09:00 ET | FN Media Group LLC
PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is characterized by...
ElmediX_blue_horizontal
ElmediX Plans Series A Round Based on Strong Signals in a Clinical Study for Pancreatic Cancer Patients at the University Hospital Antwerp (Belgium)
June 14, 2024 08:03 ET | Elmedix
A novel and innovative approach to treating metastasized cancer, starting with the very lethal grade 4 pancreatic cancer.  Earlier this year, scientists from Columbia University in New...
AIMLogo.jpg
AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference
June 10, 2024 08:55 ET | AIM ImmunoTech Inc.
OCALA, Fla., June 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will...
logo-cumulus.png
Cumulus Oncology Appoints Catherine Lewis La Torre to its Board of Directors
June 10, 2024 04:00 ET | Cumulus Oncology
EDINBURGH, Scotland, June 10, 2024 (GLOBE NEWSWIRE) -- Cumulus Oncology, Europe’s first oncology-focused biotech company creation factory, announces the appointment of Catherine Lewis La Torre to...
EnGeneIC_Logo.png
EnGeneIC and Singapore Institute of Advanced Medicine Holdings Forge Strategic Partnership to Revolutionise Cancer Treatment in Asia
June 06, 2024 21:13 ET | EnGeneIC
SYDNEY, Australia, June 06, 2024 (GLOBE NEWSWIRE) -- EnGeneIC, a clinical-stage biopharmaceutical company pioneering the development of a First-in-Class targeted nanocell for cancer therapy has...
Vaccinex logo
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease
June 06, 2024 08:30 ET | Vaccinex, Inc.
Patient visits complete in Alzheimer's Disease clinical trial. Company plans to lock database in June and to present topline data in July.
RM Primary Logo - Humble.png
Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...